Westlake Chemical Partners LP
Westlake Chemical Partners LP (WLKP) Financial Performance & Income Statement Overview
Explore the financials of Westlake Chemical Partners LP (WLKP), including yearly and quarterly data on income, cash flow, and balance sheets.
Westlake Chemical Partners LP (WLKP) Income Statement & Financial Overview
Analyze Westlake Chemical Partners LP’s WLKP earnings with segmented quarterly and yearly financial statement figures.
Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
---|---|---|---|---|
Revenue | $297.12M | $237.63M | $290.06M | $277.00M |
Cost of Revenue | $199.59M | $183.55M | $191.48M | $160.05M |
Gross Profit | $97.53M | $54.08M | $98.58M | $116.94M |
Gross Profit Ratio | $0.33 | $0.23 | $0.34 | $0.42 |
R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
SG&A Expenses | $6.30M | $7.47M | $6.56M | $7.25M |
Operating Expenses | $6.30M | $7.47M | $6.56M | $7.25M |
Total Costs & Expenses | $205.89M | $191.02M | $198.03M | $167.31M |
Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
Interest Expense | -$5.91M | -$5.54M | $5.77M | $6.70M |
Depreciation & Amortization | $0.00 | $9.73M | $27.48M | $28.11M |
EBITDA | $91.23M | $46.61M | $140.27M | $139.13M |
EBITDA Ratio | $0.31 | $0.20 | $0.48 | $0.50 |
Operating Income | $91.23M | $46.61M | $92.03M | $109.69M |
Operating Income Ratio | $0.31 | $0.20 | $0.32 | $0.40 |
Other Income/Expenses (Net) | -$5.23M | -$4.19M | -$4.44M | -$5.37M |
Income Before Tax | $86.00M | $42.42M | $87.59M | $104.32M |
Income Before Tax Ratio | $0.29 | $0.18 | $0.30 | $0.38 |
Income Tax Expense | $205000.00 | $107000.00 | $202000.00 | $216000.00 |
Net Income | $85.80M | $42.31M | $15.00M | $18.14M |
Net Income Ratio | $0.29 | $0.18 | $0.05 | $0.07 |
EPS | $0.00 | $1.20 | $0.43 | $0.51 |
Diluted EPS | $0.00 | $1.20 | $0.43 | $0.51 |
Weighted Avg Shares Outstanding | $0.00 | $35.23M | $35.24M | $35.23M |
Weighted Avg Shares Outstanding (Diluted) | $0.00 | $35.23M | $35.24M | $35.23M |
Over the past four quarters, Westlake Chemical Partners LP demonstrated steady revenue growth, increasing from $277.00M in Q3 2024 to $297.12M in Q2 2025. Operating income reached $91.23M in Q2 2025, maintaining a consistent 31% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $91.23M, reflecting operational efficiency. Net income rose to $85.80M, with EPS at $0.00. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan